RDS is primarily caused by a deficiency of surfactant, a substance that helps keep the alveoli in the lungs open.

Prematurity, maternal diabetes, and cesarean section delivery are all risk factors for RDS.

Tachypnea, retractions, and cyanosis are all typical clinical presentations of RDS.

Chest X-ray, arterial blood gas analysis, and pulse oximetry are all commonly used to confirm RDS.

Surfactant replacement therapy, oxygen therapy, and mechanical ventilation are all primary treatments for RDS.

Surfactant replacement therapy aims to improve lung function, reduce the need for mechanical ventilation, and decrease the risk of complications in RDS.

Both conventional mechanical ventilation and high-frequency oscillatory ventilation are commonly used in RDS.

Oxygen therapy aims to maintain adequate oxygen saturation, prevent hypoxemia, and improve lung function in RDS.

Bronchopulmonary dysplasia (BPD), pneumonia, and pneumothorax are all potential complications of RDS.

The prognosis of RDS depends on the severity of the condition, but generally, with early intervention, the prognosis is good. However, it can lead to long-term respiratory problems in some cases.

Administering antenatal corticosteroids to at-risk mothers, avoiding elective cesarean section deliveries, and maintaining a healthy pregnancy weight are all preventive measures for RDS.

Corticosteroids are used in the management of RDS to reduce inflammation, improve lung function, and prevent bronchopulmonary dysplasia (BPD).

Hyperglycemia, gastrointestinal bleeding, and increased risk of infection are all potential side effects of corticosteroids in the treatment of RDS.

Surfactant replacement therapy is typically continued until the infant is able to maintain adequate oxygen saturation without supplemental oxygen.

Decreased oxygen requirement, improved respiratory effort, and resolution of cyanosis are all signs of improvement in RDS.